Boğaziçi Lifesci Kandilli Deep Talks Webinar - 2

01 June 2022


Kandilli Deep Talks

Webinar – 2

1 June 2022, 6:00 - 7:30 pm (GMT+3)

 Please click the link to register:







Micro- and nano-scale technologies can have a significant impact on medicine and biology in the areas of biofabrication, cell manipulation, diagnostics and monitoring. At the convergence of these new technologies and biology, we research for enabling solutions to real-world problems at the clinic. Emerging nano-scale and microfluidic technologies integrated with biology offer innovative possibilities for creating intelligent, mobile, medical tools and devices that could transform diagnostics and monitoring, microrobotics, tissue engineering and regenerative medicine. We will present interesting applications of microfluidic technologies in IVF, cancer detection via the isolation of extracellular vesicles and microswimmers. Some of these innovative microfluidic devices have been translated into FDA approved and CE marked products, where they have been widely used by clinics around the world serving patients.


Dr. Utkan Demirci is a professor with tenure at Stanford University School of Medicine and serves as the interim director and division chief at the Canary Center for Cancer Early Detection in the Department of Radiology. He also was a faculty member earlier at the Brigham and Women’s Hospital, Harvard Medical School at the Harvard-MIT Health Sciences and Technology division prior to his appointment at Stanford. His group is focused on the development of point-of-care technologies and creating microfluidic platforms for sorting rare cells and exosomes for infectious diseases and cancer. Dr. Demirci is a fellow-elect of the American Institute of Medical and Biological Engineering, elected in 2017. He received his PhD from Stanford University in Electrical Engineering in 2005 as well as M.S. degrees in 2001 in Electrical Engineering, and in Management Science and Engineering in 2005. He has published over 200 peer-reviewed articles, 300 abstracts and proceedings, 24 book chapters and editorials, four edited books, over 25 patents pending or granted, and serves as an editorial board member for various peer-reviewed journals. His group focuses on developing innovative point-of-care technologies and creating microfluidic platforms for cancer with broad applications to multiple diseases. Dr. Demirci’s seminal work in microfluidics has led to the development of innovative platform technologies in medicine. His inventions have been licensed to numerous companies. He has co-founded several startups and serves as advisor to multiple companies including DxNow, LevitasBio, and Koek Biotech. His work has translated into several FDA approved and CE marked technologies used at the clinical settings.